Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Market Intelligence

Set Alert for Market Intelligence

Lamotrigine Leads October Increases In UK

Four presentations of epilepsy treatment lamotrigine topped WaveData’s table of the fastest-rising prices of typical generics in the UK in October.

Market Intelligence Pricing Strategies

Rasagiline Rise Outstrips Other UK Increases In September

With large treble-digit-percentage generic price rises scarce in the UK in September, a recently-launched molecule – rasagiline – showed the steepest increase, according to the latest information from market researcher WaveData.

Market Intelligence Pricing Strategies

Betahistine Leads A Raft Of UK Rises In August

With multiple generic molecules experiencing treble-digit-percentage price increases in the UK in August, betahistine tablets led the month’s biggest risers, according to WaveData.

Market Intelligence Pricing Strategies

Teva’s Francis: I Looked At All The Sexy Stuff And Overlooked Olanzapine

After launching the Uzedy long-acting formulation of risperidone in partnership with MedinCell earlier this year, Teva has stressed the “really exciting” product profile of another long-acting antipsychotic from the partnership, olanzapine, while discussing how it will avoid the safety pitfalls of legacy products in the space.

Value-Added Medicines Strategy

Xbrane: We Are Not Convinced On European IQVIA Ranibizumab Data

Swedish biosimilars player Xbrane spoke candidly about its recent launch of the company’s first product, the Stada-partnered Ximluci biosimilar to Lucentis in Europe, as it updated on the company’s ongoing hunt for a new US commercialization partner.

Sales & Earnings Strategy

Generics Bulletin Explains: The Changing US Generics Market

After a couple of years of heavy downwards pressure on US generics prices, prominent off-patent companies have pointed to a change in the pricing environment as several factors combine to reduce price erosion. Meanwhile, some firms are benefiting from first generic launches as others exit the market altogether, while injectables shortages continue to loom large.

Generic Drugs United States

UK Risks Becoming ‘Economically Unviable’ For Biosimilars

Amid increasing financial pressure from the VPAS rebate scheme and a lack of a national uptake strategy, the BGMA has warned that the UK risks losing its leading position in European biosimilars and could become altogether “economically unviable” for biosimilars suppliers.

Market Intelligence Biosimilars

July Wholesaler Hike Sees UK Olanzapine Prices Spike

July brought UK price spikes for multiple presentations of generic olanzapine orodispersible tablets. Market researcher WaveData reveals the reason behind the increases.

Market Intelligence Pricing Strategies

PBMs Denying Patients Access To Lantus Biosimilars, Says Report

Biosimilars of insulin glargine have failed to capture significant market share since their launch in 2020 as pharmacy benefit managers favor the originator’s higher list price for its associated rebates, according to a report from the Biosimilars Council.

Biosimilars Market Access

Savvy Pricing Practices Enabling Deep Discounts For Adalimumab And Glargine

The second quarterly report on the biosimilars industry from Samsung Bioepis has drawn attention to how pricing strategies are being used to enable discounts for adalimumab and insulin glargine.

Biosimilars Pricing Strategies

Pantoprazole Leads Off UK Price Spikes In June

Amid triple-digit-percentage average price rises for several generic molecules in the UK during June 2023, pantoprazole topped the list.

Market Intelligence Pricing Strategies

Samsung Bioepis Sees Information Driving Utilization

By offering a detailed quarterly report on the US biosimilars market, Samsung Bioepis is hoping to help drive awareness and understanding, ultimately pushing up utilization, the firm’s US head of market access Tom Newcomer tells Generics Bulletin.

Biosimilars Market Intelligence

UK Olanzapine Prices Rocket Up In May

Three presentations of olanzapine orodispersible tablets topped our table of the UK generics market’s Biggest Risers for May 2023.

Market Intelligence Pricing Strategies

Ivabradine Prices Rise High Among Recent UK Launches In April

Ivabradine stood out among recently-launched UK generics with an average price rise of more than a third in April, according to the latest figures from market researcher WaveData.

Market Intelligence Pricing Strategies

Samsung Bioepis Biosimilars Report Sees Lower Price Boosting Uptake

Samsung Bioepis has published the first in a planned series of reports on the US biosimilars market, including insights into pricing, uptake and market share for various biosimilars.

Biosimilars Market Intelligence

Perindopril And Pramipexole Prices Peak In March

Two products featured highly among the fastest-rising UK generics prices in March, but for different reasons.

Market Intelligence Generic Drugs
See All